Piper Sandler analyst David Amsellem downgraded Horizon Therapeutics (HZNP) to Neutral from Overweight with a price target of $116.50, up from $110, after Horizon announced a deal to be acquired by Amgen (AMGN) for $116.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HZNP:
- Horizon Therapeutics downgraded to Hold from Buy at Stifel
- Unusually active option classes on open December 12th
- Amgen (NASDAQ:AMGN) to Buy Horizon for $27.8B; HZNP Stock Rallies
- Amgen to acquire Horizon Therapeutics for $116.50 per share in cash
- Amgen nears deal to acquire Horizon Therapeutics, WSJ reports